MNG975
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.351
- UNFOLDED_PROTEIN_RESPONSE+0.301
- MITOTIC_SPINDLE+0.290
- PI3K_AKT_MTOR_SIGNALING+0.281
- TGF_BETA_SIGNALING+0.266
- ADIPOGENESIS+0.265
- UV_RESPONSE_DN+0.239
- MYC_TARGETS_V2+0.208
- WNT_BETA_CATENIN_SIGNALING+0.197
- DNA_REPAIR+0.187
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.517
- COAGULATION-0.313
- KRAS_SIGNALING_DN-0.297
- TNFA_SIGNALING_VIA_NFKB-0.279
- ANGIOGENESIS-0.277
- APICAL_SURFACE-0.267
- INFLAMMATORY_RESPONSE-0.224
- COMPLEMENT-0.215
- ESTROGEN_RESPONSE_LATE-0.212
- SPERMATOGENESIS-0.189
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1043 | — | — | 0.803 |
| 2 | MNG1216 | — | — | 0.794 |
| 3 | MNG812 | — | — | 0.792 |
| 4 | MNG1224 | — | — | 0.787 |
| 5 | MNG362 | — | — | 0.781 |
| 6 | MNG1042 | — | — | 0.775 |
| 7 | MNG170 | — | — | 0.767 |
| 8 | MNG196 | — | — | 0.766 |
| 9 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.764 |
| 10 | MDT-AP-0544 | Med | Medulloblastoma | 0.762 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.351 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.301 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.281 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.266 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.265 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.239 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.208 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.197 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.187 | Idelalisib | — uncovered |
| PEROXISOME | 0.146 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.145 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.114 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.097 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.068 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.067 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.062 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.042 | Inavolisib | — uncovered |
| APOPTOSIS | 0.035 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.035 | Inavolisib | — uncovered |